English
Back
Download
Log in to access Online Inquiry
Back to the Top

Update

$PDS Biotechnology (PDSB.US)$ PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
2 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77%
11/53 (21%) of patients experienced 90-100% tumor shrinkage
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3317 Views
Comment
Sign in to post a comment
    4916
    Followers
    24
    Following
    70K
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More